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Introduction
Periorbital edema without proteinuria is a rare and often
difficult to manage manifestation of SLE. The use of
belimumab for treatment of this complication has not
been previously described in the pediatric literature.
Objectives
To describe the use of belimumab for treatment of ster-
oid-dependent chronic periorbital edema in new onset
non-renal SLE.
Methods
Case report: A 16 year old white female presented with
a three month history of periorbital edema in the setting
of positive lupus serologies, synovitis, and hypocomple-
mentemia. She had failed treatment with anti-histamines
and had responded well to the use of oral steroids, but
her symptoms quickly recurred upon tapering off ster-
oids. Over the following six months, treatment with
hydroxychloroquine and methotrexate failed to provide
any steroid-sparing benefit. Addition of a three month
trial of omalizumab also failed to provide any benefit. IV
belimumab at 10 mg/kg monthly, was initiated and con-
tinued upon one year follow-up.
Results
Treatment with belimumab resulted in complete resolu-
tion of the patient’s periorbital edema, allowing her to
discontinue the use of steroids within a month of start-
ing this agent. No adverse reactions have been observed
upon one-year follow up, and the patient’s symptoms
remain well controlled off steroids.
Conclusion
Belimumab may serve as a safe and effective steroid
sparing agent for management periorbital edema asso-
ciated with non-renal SLE.
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